- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT02206906
Incentives to Promote Medication Adherence Among HIV-Infected Youth
Investigation of Incentives to Promote Medication Adherence Among HIV-Infected Youth on Antiretroviral Therapy
Przegląd badań
Szczegółowy opis
PRIMARY OBJECTIVE:
- To describe the effects of a novel incentive intervention model on HIV-infected youths' patterns of antiretroviral medication adherence.
SECONDARY OBJECTIVES:
- To evaluate the feasibility of an outpatient incentive intervention model.
- To assess participant satisfaction with the incentive intervention model.
- To evaluate the effect of an outpatient incentive intervention model on targeted health behaviors (numbers of missed appointments and STI diagnoses).
- To measure the effect of the incentive intervention on HIV viral load and CD4+ count.
- To determine the overall and per patient cost of the incentive intervention model.
- To describe associations between adherence measures: real-time medication monitor data, pharmacy pill count, pharmacy prescription pick-up data, medication possession ratio, and self-report.
Upon enrollment, participants will receive education and a real-time medication monitor. Participants will be followed monthly in the clinic and will be prescribed thirty-day supplies of medication. During weeks 1-4 participants will establish a baseline with the real-time medication monitor. During weeks 5-28, participants will receive remote incentives based on their level of medication adherence as measured by the real-time medication monitor. Additional lottery-style incentives will occur at regular follow-up visits. No incentives will be applied during weeks 29-48. Participants will complete the protocol at the week 48 visit.
Typ studiów
Zapisy (Rzeczywisty)
Kontakty i lokalizacje
Lokalizacje studiów
-
-
Tennessee
-
Memphis, Tennessee, Stany Zjednoczone, 38105
- St. Jude Children'S Research Hospital
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Metoda próbkowania
Badana populacja
Opis
Inclusion Criteria:
- ≥16 and ≤ 24 years old
- Documented diagnosis of HIV
- Adolescent is aware of his/her HIV diagnosis
- Adolescent understands either written or spoken English.
- Adolescent is willing and able to provide informed consent or assent.
- Adolescent has access to a phone and the internet at the time of enrollment.
Adolescent meets the definition of inadequate ARV adherence, which is any of the following in the previous 12 months:
- < 80% adherent to any ARV by pharmacy pill count
- ≥ 7 days delay in scheduled ARV prescription pick-up
- Detectable viral load after being on ARVs for at least 12 weeks
Exclusion Criteria:
- Adolescent has a documented diagnosis of mental retardation or a significant motor or sensory impairment that would preclude participation.
- Adolescent has a documented acute psychiatric illness, including suicidal ideation, homicidal ideation or active psychosis.
- Adolescent was diagnosed with HIV in the previous 6 months.
- Adolescent has a planned transition to alternative care setting prior to study completion (e.g. relocation, pregnancy or planned pregnancy, transition to adult care).
- Concurrent enrollment on a research study with an intervention targeted at increasing adherence to antiretroviral regimens.
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Modele obserwacyjne: Kohorta
- Perspektywy czasowe: Spodziewany
Kohorty i interwencje
Grupa / Kohorta |
Interwencja / Leczenie |
---|---|
Study Participants
All participants who meet eligibility requirements and who consent to participation will use an incentive intervention model.
|
All participants will receive a real-time electronic medication monitor to monitor daily pill-taking behavior.
Participants with qualifying levels of adherence will receive a weekly incentive during the intervention period.
At all clinic visits participants will participate in a lottery incentive to reinforce clinic attendance and negative STI screening tests.
|
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
---|---|---|
Percentage of dosages taken within 2 hours of prescribed time per month
Ramy czasowe: Monthly through week 48
|
Data collected by a real-time medication monitor that records pillbox opening times.
|
Monthly through week 48
|
Pharmacy pill count
Ramy czasowe: Monthly from 6 months prior to study start through week 48
|
Pharmacy pill count data is collected at each participant encounter, approximately once per month.
|
Monthly from 6 months prior to study start through week 48
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
---|---|---|
Feasibility - Accrual percentage
Ramy czasowe: End of study (week 48)
|
Number of people enrolled in study/number approached for enrollment.
|
End of study (week 48)
|
Feasibility - Drop out rate
Ramy czasowe: End of study (week 48)
|
Number of people ending protocol early/ total enrollment
|
End of study (week 48)
|
Feasibility - Participant reported device concerns
Ramy czasowe: End of study (week 48)
|
Problems with the Wisepill devices as spontaneously reported by participants or as assessed at routine follow-up.
|
End of study (week 48)
|
Feasibility - Device replacement rate
Ramy czasowe: End of study (week 48)
|
Number of devices requiring replacement due to loss/theft/breakage
|
End of study (week 48)
|
Feasibility - Contact failure rate
Ramy czasowe: End of study (week 48)
|
Number of failed attempts to contact participants/total number of contact attempts made
|
End of study (week 48)
|
Feasibility - Staff hours per week
Ramy czasowe: End of study (week 48)
|
Hours spent providing remote incentives
|
End of study (week 48)
|
Feasibility - Adverse effects of incentives
Ramy czasowe: End of study (week 48)
|
Unexpected risks/harms of providing incentives as self-reported by participants.
|
End of study (week 48)
|
Percentage of participants who are satisfied with the incentive intervention
Ramy czasowe: Enrollment (week 0) and end of study (week 48)
|
To assess participant satisfaction with the incentive intervention model.
Patient satisfaction, assessed by ACASI survey, will be summarized and tabulated for baseline (week 0) and follow-up (week 48) measurements.
|
Enrollment (week 0) and end of study (week 48)
|
Effect of incentives on missed appointment rate
Ramy czasowe: Enrollment (week 0) and end of study (week 48)
|
Descriptive statistics of numbers of missed appointments such as mean, interquartile range and median, during each study phase will be computed and compared
|
Enrollment (week 0) and end of study (week 48)
|
Effect of incentives on STI rates
Ramy czasowe: Enrollment (week 0) and end of study (week 48)
|
Descriptive statistics of numbers of STI rates such as mean, interquartile range and median, during each study phase will be computed and compared
|
Enrollment (week 0) and end of study (week 48)
|
Change in biological parameters
Ramy czasowe: At weeks 0, 12, 24, 36 and 48
|
To measure the effect of the incentive intervention on HIV viral load and CD4+ count.
HIV viral load and CD4+ count measured at week 0, 12, 24, 36 and 48 will be summarized and plotted by descriptive statistics, such as mean and standard deviation.
Mixed effects models will be applied to explore the effect of the intervention on HIV viral load and CD4+ count.
|
At weeks 0, 12, 24, 36 and 48
|
Overall cost of incentive intervention
Ramy czasowe: End of study (week 48)
|
To determine the overall and per patient cost of the incentive intervention model the accumulated overall and per patient cost till week 48 will be summarized and tabulated.
|
End of study (week 48)
|
Association between adherence measures
Ramy czasowe: End of study (week 48)
|
To describe associations between adherence measures: Wisepill data, pharmacy pill count, pharmacy prescription pick-up data, medication possession ratio, and self-report.
Associations of Wisepill adherence rates with pill count and pick up rates will be described by Pearson or Spearman's correlation coefficients and intraclass correlation coefficients as appropriate.
|
End of study (week 48)
|
Współpracownicy i badacze
Śledczy
- Główny śledczy: Ronald Dallas, PhD, St. Jude Children'S Research Hospital
Publikacje i pomocne linki
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów
Zakończenie podstawowe (Rzeczywisty)
Ukończenie studiów (Rzeczywisty)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Oszacować)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Oszacować)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Inne numery identyfikacyjne badania
- INMED
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .
Badania kliniczne na HIV
-
University of Alabama at BirminghamMobile County Health Deparment; Alabama Department of Public HealthRekrutacyjnyHIV | Test na HIV | Związek HIV z opieką | Leczenie HIVStany Zjednoczone
-
ANRS, Emerging Infectious DiseasesHopital Universitaire Robert-Debre; Institut de Recherche pour le Developpement i inni współpracownicyNieznanyHIV | Dzieci niezakażone wirusem HIV | Dzieci narażone na HIVKamerun
-
University of MinnesotaWycofaneZakażenia wirusem HIV | HIV/AIDS | HIV | AIDS | Problem z AIDS/HIV | AIDS i infekcjeStany Zjednoczone
-
French National Agency for Research on AIDS and...Elizabeth Glaser Pediatric AIDS FoundationZakończonyPartnerskie testy na obecność wirusa HIV | Porady dotyczące HIV dla par | Komunikacja pary | Zapadalność na HIVKamerun, Republika Dominikany, Gruzja, Indie
-
Africa Health Research InstituteLondon School of Hygiene and Tropical Medicine; University College, London; University... i inni współpracownicyRekrutacyjnyHIV | Test na HIV | Połączenie z opiekąAfryka Południowa
-
CDC FoundationGilead SciencesNieznanyProfilaktyka przed ekspozycją na HIV | Chemioprofilaktyka HIVStany Zjednoczone
-
Hospital Clinic of BarcelonaZakończonyInhibitory integrazy, HIV; INHIB PROTEAZY HIVHiszpania
-
University of Maryland, BaltimoreWycofaneHIV | Przeszczep nerki | Zbiornik HIV | CCR5Stany Zjednoczone
-
Helios SaludViiV HealthcareNieznanyHIV | Zakażenie HIV-1Argentyna
-
Erasmus Medical CenterJeszcze nie rekrutacjaZakażenia wirusem HIV | HIV | Zakażenie HIV-1 | Zakażenie wirusem HIV IHolandia
Badania kliniczne na Incentive intervention model
-
Munich Municipal HospitalTechnical University of Munich; University of RegensburgNieznany
-
Medical College of WisconsinRekrutacyjnyCukrzyca typu 2Stany Zjednoczone
-
Sarah MorrowLawson Health Research InstituteZakończony
-
Cukurova UniversityZakończonyNasycenie tlenem | Spirometria motywacyjnaIndyk
-
Gia MuddNational Institute of Nursing Research (NINR)RekrutacyjnyChoroby układu krążenia | Cukrzyca typu 2Stany Zjednoczone
-
Columbia UniversityNational Institute of Mental Health (NIMH)ZakończonySchizofrenia | Zaburzenie psychotyczneBrazylia, Chile
-
Vanderbilt University Medical CenterRejestracja na zaproszeniePoważny uraz mózguStany Zjednoczone
-
Johnson & Johnson Surgical Vision, Inc.ZakończonyZaćmaStany Zjednoczone
-
Uludag UniversityZakończony
-
VA Office of Research and DevelopmentZakończonyZaburzenia stresowe, pourazoweStany Zjednoczone